T cells in idiopathic pulmonary fibrosis: crucial but controversial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) has been extensively studied in recent decades due to its rising incidence and high mortality. Despite an abundance of research, the mechanisms, immune-associated mechanisms, of IPF are poorly understood. While defining immunopathogenic mechanisms as the primary pathogenesis is controversial, recent studies have verified the contribution of the immune system to the fibrotic progression of IPF. Extensive evidence has shown the potential role of T cells in fibrotic progression. In this review, we emphasize the features of T cells in IPF and highlight the controversial roles of different subtypes of T cells or even two distinct effects of one type of T-cell in diverse settings, and multiple chemokines and cell products are discussed. Furthermore, we discuss the potential development of treatments targeting the immune molecules of T cells and the feasibility of immune therapies for IPF in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incidence and Outcomes of Acute Lung Injury
Rubenfeld, G. D., Caldwell, E., Peabody, E., Weaver, J., Martin, D. P., Neff, M., Stern, E. J., & Hudson, L. D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050333 · Cited by 3,684
Liang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330 · cited 1×
“The classical cytokines secreted by Th17 cells, IL-17 and IL-22, contribute to host defense in many infective circumstances but also accelerate the inflammatory process in multiple autoimmune diseases, such as rheumatoid arthritis [58, 59].”
BackgroundPhenotypic and functional features of human Th17 cells
Annunziato, F., Cosmi, L., Santarlasci, V., Maggi, L., Liotta, F., Mazzinghi, B., Parente, E., Filì, L., Ferri, S., Frosali, F., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070663 · Cited by 1,861 · cited 1×
“Moreover, the Th17 lineage is characterized by low susceptibility to regulatory T cells (Tregs) [70].”
BackgroundFibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Lambrecht, B. N., & Hammad, H. (2015) · Nature Immunology · doi:10.1038/ni.3049 · Cited by 1,673 · cited 1×
“Furthermore, apart from infectious diseases with definite aetiologies, many pulmonary diseases, such as asthma [23] and acute respiratory distress syndrome [24], are related to immune responses mediated by T lymphocytes to varying extents, and pulmonary fibrosis is no exception [25].”
BackgroundGruver, A., Hudson, L., & Sempowski, G. (2007) · The Journal of Pathology · doi:10.1002/path.2104 · Cited by 834 · cited 1×
“The thymus is responsible for producing naïve T cells and is gradually replaced by fatty tissues in individuals over the age of sixty [40], and the adaptive immune system decays accordingly.”
BackgroundBleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730 · cited 1×
“IL-22 shows no significant variations in patients with IPF compared to normal individuals [60].”
BackgroundA placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030511 · Cited by 652 · cited 1×
“Furthermore, a striking increase in Th2 cytokines was detected in the BAL fluid of IPF patients [51, 52].”
BackgroundKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531 · cited 1×
“Th1-type chemokine patterns in IPF showed that lung fibroblasts tend to induce a Th1-type immune response under normal conditions; that is, Th1 cells participate in the normal scar healing process [50].”
BackgroundFranceschi, C., Bonafè, M., & Valensin, S. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00513-7 · Cited by 495
Cited by
The senescence-associated secretory phenotype and its physiological and pathological implications
Wang, B., Han, J., Elisseeff, J. H., & Demaria, M. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00727-x · Cited by 948
Terekhova, M., Swain, A., Bohacova, P., Aladyeva, E., Arthur, L., Laha, A., Mogilenko, D. A., Burdess, S., Sukhov, V., Kleverov, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.10.013 · Cited by 199
Bhattacharya, M., & Ramachandran, P. (2023) · Nature Immunology · doi:10.1038/s41590-023-01551-9 · Cited by 148
Yan, T., Liu, J., Liu, Y., Gu, W., Liu, J., Li, Y., Lv, R., Zhang, C., Ding, J., Zha, C., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00542-0
Metadata
- Authors
- Deng, L., Huang, T., & Zhang, L.
- Venue
- Cell Death Discovery
- Published
- 2023-02-14
- Volume
- 9
- Issue
- 1
- Pages
- 62-62
- ISSN
- 2058-7716 (ISSN-L)
- OpenAlex
- W4320725974
- Cited by
- 74
- References
- 29
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T cells in idiopathic pulmonary fibrosis: crucial but controversial. https://app.cochat.ai/papers/10.1038/s41420-023-01344-x
- The paper
- Deng, L., Huang, T., & Zhang, L. (2023). T cells in idiopathic pulmonary fibrosis: crucial but controversial. Cell Death Discovery. https://doi.org/10.1038/s41420-023-01344-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.